Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3919233 | 0.86 | SMN1; SMN2 (0.49) | ACHE | |
| SCHEMBL4674082 | 0.83 | KMT2A (0.51) | — | |
| SCHEMBL63100 | 0.80 | HDAC1 (0.61) | HDAC1HDAC6MTNR1AMTNR1B | |
| SCHEMBL3930468 | 0.79 | FFAR4 (0.53) | ACHESIRT2HDAC1HDAC6MTNR1A | |
| SCHEMBL3920495 | 0.79 | ALDH1A1 (0.43) | FFAR1 | |
| SCHEMBL14051488 | 0.77 | ACHE (0.47) | ACHE | |
| SCHEMBL9754340 | 0.77 | BCHE (0.55) | ACHEHDAC1HDAC6 | |
| SCHEMBL8134234 | 0.76 | CHRNB2 (0.54) | ACHECYP2D6 | |
| SCHEMBL9804265 | 0.76 | FFAR1 (0.60) | SIRT2FFAR1 | |
| SCHEMBL4644508 | 0.76 | SIRT2 (0.48) | SIRT2HDAC1HDAC6MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735280-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | Kalypsys, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005115983-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | KALYPSYS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | PPARA, PPARG, PPARD | ACHE 3680/4885SIRT2 308/4885HDAC1 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.